Akademik Veri Yönetim Sistemi
TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, cilt.48, sa.4, ss.294-298, 2013 (ESCI)
Aim: Short stature, a common feature of Turner syndrome, may be treated effectively by recombinant human growth hormone (rhGH). In this study we aimed to evaluate response to rhGH in the first three years of therapy. Material and Method: Medical records of 46 girls with Turner syndrome treated with rhGH were evaluated retrospectively. Karyotypes, age of admission to the hospital, age of the beginning of rhGH therapy, the height of the mother and father were recorded. Data including, height and weight, growth velocity, dose of rhGH therapy, bone age and predicted height of subjects at the beginning, after first, second and thirds years of rhGH therapy were recorded. Difference between target height Z-score and height Z-score is defined as delta Z-score. Results: Age of admission to hospital, age of beginning of rhGH therapy, target height were 10.2 +/- 3.8 years, 11.54 +/- 3.03 years and 157.0 +/- 6.0 cm respectively. Height Z-score at the beginning, at the end of first, second and thirds year of therapy were -3.76 +/- 1.00, -3.37 +/- 1.01, -2.99 +/- 0.97, -2.82 +/- 1.01 respectively and growth velocity were 3.24 +/- 1.05, 6.53 +/- 1.52, 5.77 +/- 1.53, 5.19 +/- 1.25 cm/per year respectively. Bivariate correlation analyzes have revealed that at the first year of therapy growth velocity was correlated negatively with chronologic and bone age of beginning to GH therapy, delta Z-score and father's height and positively with rhGH dose. Conclusions: Major factors to affect response to rhGH therapy were age, rhGH dose and delta Z-score. As the major predictor of the growth velocity is age at the beginning of the therapy, these girls must be treated with rhGH as soon as possible after diagnosis.